News & Events

Update from AML human trial in Miami

04 May|

Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:

8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.

In cohort 1 (dose=6mg/m^2) three patients were enrolled.

The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third

Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors

17 Feb|

The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.

PHASE 1B/2A Clinical trial started

13 Apr|

The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

09 Jan|

Cooperation with Harvard Medical School (MGH)

27 Oct|

ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases